Role of radiation therapy in the management of pancreatic cancer

Journal of Surgical Oncology

Volumn 107, Issue 1, 2013, Pages 86-96

  Goodman, Karyn A ^a   Hajj, Carla ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

locally advanced pancreatic cancer; radiotherapy; resectable pancreatic cancer

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PACLITAXEL;

ADD ON THERAPY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DISTANT METASTASIS; DOSIMETRY; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTRAOPERATIVE RADIOTHERAPY; LAPAROTOMY; LEUKOPENIA; LIFE EXPECTANCY; MICROMETASTASIS; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE NAUSEA AND VOMITING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; THROMBOCYTOPENIA;

CHEMORADIOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 84871335067     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23137     Document Type: Article

References (74)

1. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. National Cancer Institute Annual Cancer Statistics Review 1973-1988, Bethesda, MD 1991, Dept. of Health and Human Services, (NIH publication no. 91-2789).
3. Gudjonsson B:, Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284-2303.
4. Raimondi S, Maisonneuve P, Lowenfels AB:, Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699-708.
5. Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
6. Yeo CJ, Cameron JL, Sohn TA, et al.: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997; 226: 248-257 (discussion 257-60).
7. Saif MW:, Adjuvant treatment of pancreatic cancer in 2009: Where are we? Highlights from the 45th annual ASCO meeting. Orlando, FL, May USA. 29-June 2, 2009. JOP 2009; 10: 373-377 (Review).
8. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549-557.
9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782 (discussion 782-4).
10. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210 (Erratum in: N Engl J Med. 2004 Aug 12; 351(7) 726).
11. Regine WF, Winter KA, Abrams R, et al.: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18: 1319-1326.
12. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267Y277.
13. Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-633 (discussion 633-6).
14. Picozzi VJ, Kozarek RA, Traverso LW:, Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476-480.
15. Herman JM, Swartz MJ, Hsu CC, et al.: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-3510.
16. Hsu CC, Herman JM, Corsini MM, et al.: Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010; 17: 981-990 (Epub 2010 Jan 20).
17. Picozzi VJ, Abrams RA, Decker PA:, Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011; 22: 348-354 (Epub 2010 Jul 29).
18. Lim KH, Chung E, Khan A, et al.: Neoadjuvant therapy of pancreatic cancer: The emerging paradigm ? Oncologist 2012; 17: 192-200.
19. Evans DB, Rich TA, Byrd DR, et al.: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335-1339.
20. Pisters PW, Abbruzzese JL, Janjan NA, et al.: Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 3843-3850.
21. Pisters PW, Wolff RA, Janjan NA, et al.: Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006; 13: 150-158.
22. Kozak KR, Kachnic LA, Adams J, et al.: Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys 2007; 68: 1557-1566.
23. Hong TS, Ryan DP, Blaszkowsky LS, et al.: Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys 2011; 79: 151-157.
24. Mehta VK, Poen JC, Ford J, et al.: Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001; 24: 155-159.
25. Massucco P, Capussotti L, Magnino A, et al.: Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival. Ann Surg Oncol 2006; 13: 1201-1208.
26. Small W Jr, Berlin J, Freedman GM, et al.: Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2008; 26: 942-947.
27. Patel M, Hoffe S, Malafa M, et al.: Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011; 104: 155-161.
28. Stokes JB, Nolan NJ, Stelow EB, et al.: Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011; 18: 619-627.
29. Wayne JD, Abdalla EK, Wolff RA, et al.: Localized adenocarcinoma of the pancreas: The rationale for preoperative chemoradiation. Oncologist 2002; 7: 34-45.
30. Moertel CG, Frytak S, Hahn RG, et al.: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710.
31. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80: 751-755.
32. Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599 (Epub 2008 May 7).
33. Loehrer PJ Sr, Feng Y, Cardenes H, et al.: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105-4112 (Epub 2011 Oct 3).
34. Huguet F, André T, Hammel P, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
35. Schellenberg D, Kim J, Christman-Skieller C, et al.: Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011; 81: 181-188 (Epub 2011 May 5).
36. Didolkar MS, Coleman CW, Brenner MJ, et al.: Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010; 14: 1547-1559 (Epub 2010 Sep 14).
37. Rwigema JC, Heron DE, Parikh SD, et al.: Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. J Gastrointest Cancer 2010; 43: 70-76.
38. Mahadevan A, Jain S, Goldstein M, et al.: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010; 78: 735-742 (Epub 2010 Feb 18).
39. Seo Y, Kim MS, Yoo S, et al.: Stereotactic body radiation therapy boost in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2009; 75: 1456-1461 (Epub 2009 Sep 23).
40. Chang DT, Schellenberg D, Shen J, et al.: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009; 115: 665-672.
41. Schellenberg D, Goodman KA, Lee F, et al.: Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008; 72: 678-686 (Epub 2008 Apr 18).
42. Koong AC, Christofferson E, Le QT, et al.: Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005; 63: 320-323.
43. Hoyer M, Roed H, Sengelov L, et al.: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005; 76: 48-53.
44. Koong AC, Le QT, Ho A, et al.: Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1017-1021.
45. Wong AA, Delclos ME, Wolff RA, et al.: Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2005; 28: 227-233.
46. Wilkowski R, Thoma M, Bruns C, et al.: Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 2006; 7: 34-40.
47. LoSasso T, Chui CS, Kutcher GJ, et al.: The use of a multi-leaf collimator for conformal radiotherapy of carcinomas of the prostate and nasopharynx. Int J Radiat Oncol Biol Phys 1993; 25: 161-170.
48. Burman C, Chui CS, Kutcher G, et al.: Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: A strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 39: 863-873.
49. Zelefsky MJ, Cowen D, Fuks Z, et al.: Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460-2468.
50. Zelefsky MJ, Fuks Z, Hunt M, et al.: High-dose intensity modulated radiation therapy for prostate cancer; early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53: 1111-1116.
51. Zelefsky MJ, Fuks Z, Leibel SA:, Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 2002; 12: 229-237.
52. Fuks Z, Leibel SA, Ling CCA:, Practical Guide to Intensity-Modulated Radiation Therapy. Published in Cooperation with Members of the Staff of Memorial Sloan-Kettering Cancer Center. Wisconsin: Medical Physics Publishing; 2003.
53. Ling CC, Burman CM, Chui CS, et al.: Conformal radiation treatment of prostate cancer using inversely planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 1996; 35: 721-730.
54. Leibel SA, Fuks Z, Zelefsky MJ, et al.: Intensity-modulated radiotherapy. Cancer J 2002; 8: 164-176.
55. Crane CH, Antolak JA, Rosen II, et al.: Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 2001; 30: 123-132.
56. Bai YR, Wu GH, Guo WJ, et al.: Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: Results of feasibility study. World J Gastroenterol 2003; 9: 2561-2564.
57. Milano MT, Chmura SJ, Garofalo MC, et al.: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004; 59: 445-453.
58. Ben-Josef E, Shields AF, Vaishampayan U, et al.: Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 59: 454-459.
59. Fuss M, Wong A, Fuller CD, et al.: Image-guided intensity-modulated radiotherapy for pancreatic carcinoma. Gastrointest Cancer Res 2007; 1: 2-11.
60. Yovino S, Poppe M, Jabbour S, et al.: Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011; 79: 158-162.
61. Huguet F, Wu A, Shi W, et al.: Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves prolonged survival. Ann Oncol, submitted.
62. Varadarajulu S, Trevino JM, Shen S, et al.: The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: A case series. Endoscopy 2010; 42: 423-425.
63. Peretz T, Nori D, Hilaris B, et al.: Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 1989; 17: 931-935.
64. Mohiuddin M, Cantor RJ, Biermann W, et al.: Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1988; 14: 79-84.
65. Shipley WU, Nardi GL, Cohen AM, et al.: Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: A comparative study to surgical resection. Cancer 1980; 45: 709-714.
66. Dobelbower RR Jr, Merrick HW III, Ahuja RK, et al.: 125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. Cancer 1986; 58: 2185-2195.
67. Montemaggi P, Dobelbower R, Crucitti F, et al.: Interstitial brachytherapy for pancreatic cancer: Report of seven cases treated with 125I and a review of the literature. Int J Radiat Oncol Biol Phys 1991; 21: 451-457.
68. Syed AM, Puthawala AA, Neblett DL:, Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer 1983; 52: 808-813.
69. Al-Abdulla AS, Hussey DH, Olson MH, et al.: Experience with fast neutron therapy for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1981; 7: 165-172.
70. Shibamoto Y, Manabe T, Baba N, et al.: High dose, external beam and intraoperative radiotherapy in the treatment of resectable and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 1990; 19: 605-611.
71. Hiraoka T, Uchino R, Kanemitsu K, et al.: Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol 1990; 7: 201-207.
72. Ozaki H, Kinoshita T, Kosuge T, et al.: Effectiveness of multimodality treatment for resectable pancreatic cancer. Int J Pancreatol 1990; 7: 195-200.
73. Sindelar WF, Kinsella T:, Randomized trial of intraoperative radiotherapy in unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 12: 148. 1986.
74. Tepper JE, Shipley WU, Warshaw AL, et al.: The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol 1987; 5: 579-584.